503 related articles for article (PubMed ID: 28133811)
21. Progress and obstacles in the development of an AIDS vaccine.
Letvin NL
Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
[TBL] [Abstract][Full Text] [Related]
22. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
23. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
Kim JH; Excler JL; Michael NL
Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
[TBL] [Abstract][Full Text] [Related]
24. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
Haut LH; Ertl HC
J Leukoc Biol; 2009 Oct; 86(4):779-93. PubMed ID: 19597003
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 vaccine clinical trials: the Brazilian experience.
Ersching J; Pinto AR
Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156
[TBL] [Abstract][Full Text] [Related]
26. Current issues in the development of a vaccine to prevent human immunodeficiency virus: insights from the society of infectious diseases pharmacists.
Sahloff EG
Pharmacotherapy; 2005 May; 25(5):741-7. PubMed ID: 15899735
[TBL] [Abstract][Full Text] [Related]
27. HIV vaccines: lessons learned and the way forward.
Kim JH; Rerks-Ngarm S; Excler JL; Michael NL
Curr Opin HIV AIDS; 2010 Sep; 5(5):428-34. PubMed ID: 20978385
[TBL] [Abstract][Full Text] [Related]
28. Sieve analysis in HIV-1 vaccine efficacy trials.
Edlefsen PT; Gilbert PB; Rolland M
Curr Opin HIV AIDS; 2013 Sep; 8(5):432-6. PubMed ID: 23719202
[TBL] [Abstract][Full Text] [Related]
29. AIDS vaccine development: the long and winding road.
Garber DA; Feinberg MB
AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
[TBL] [Abstract][Full Text] [Related]
30. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses.
Bolhassani A; Kardani K; Vahabpour R; Habibzadeh N; Aghasadeghi MR; Sadat SM; Agi E
Immunol Lett; 2015 Dec; 168(2):366-73. PubMed ID: 26518142
[TBL] [Abstract][Full Text] [Related]
31. No acquisition: a new ambition for HIV vaccine development?
Lakhashe SK; Silvestri G; Ruprecht RM
Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
[TBL] [Abstract][Full Text] [Related]
32. Modeling HIV vaccine trials of the future.
Gilbert PB; Huang Y; Janes HE
Curr Opin HIV AIDS; 2016 Nov; 11(6):620-627. PubMed ID: 27662407
[TBL] [Abstract][Full Text] [Related]
33. Conference on advances in AIDS vaccine development--1993. Summary: correlates of HIV Immunity Working Group.
Sheppard H; Bridges SH; Mathieson BJ; Walker MC; Weinhold K
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S171-6. PubMed ID: 7865294
[No Abstract] [Full Text] [Related]
34. Systems biology and the quest for correlates of protection to guide the development of an HIV vaccine.
Kuri-Cervantes L; Fourati S; Canderan G; Sekaly RP
Curr Opin Immunol; 2016 Aug; 41():91-97. PubMed ID: 27392184
[TBL] [Abstract][Full Text] [Related]
35. Epitope-vaccine strategy against HIV-1: today and tomorrow.
Liu Z; Xiao Y; Chen YH
Immunobiology; 2003; 208(4):423-8. PubMed ID: 14748515
[TBL] [Abstract][Full Text] [Related]
36. Improved outlook on HIV-1 prevention and vaccine development.
Vasan S; Michael NL
Expert Opin Biol Ther; 2012 Aug; 12(8):983-94. PubMed ID: 22583109
[TBL] [Abstract][Full Text] [Related]
37. New directions for HIV vaccine development from animal models.
McChesney MB; Miller CJ
Curr Opin HIV AIDS; 2013 Sep; 8(5):376-81. PubMed ID: 23836045
[TBL] [Abstract][Full Text] [Related]
38. Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1.
Pittala S; Morrison KS; Ackerman ME
Curr Opin HIV AIDS; 2019 Jul; 14(4):253-264. PubMed ID: 31033729
[TBL] [Abstract][Full Text] [Related]
39. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.
Pantaleo G; Koup RA
Nat Med; 2004 Aug; 10(8):806-10. PubMed ID: 15286782
[TBL] [Abstract][Full Text] [Related]
40. Current progress in the development of HIV vaccines.
Spearman P
Curr Pharm Des; 2006; 12(9):1147-67. PubMed ID: 16515492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
